Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993107 · ClinicalTrials.gov registry record · Phase 3
PALISADE Follow-on Study (ARC004)
A Phase 3 study, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT02993107: Completed Phase 3 study, sponsored by Aimmune Therapeutics.
NCT02993107 is a Phase 3 study that has completed, run by Aimmune Therapeutics. The registered enrollment target is 388 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993107, a Phase 3 study, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
Primary Outcome
Percentage of subjects ages 4-17 with at-least 1 TEAE, including serious adverse events, during the overall study period. The percentage of subjects reporting at least 1 TEAE by maximum reported severity is also presented using the 5-point CTCAE severity grading scale. All safety evaluations were conducted using the safety population (all subjects who received at least 1 dose of AR101 during ARC004), age 4-17 years. Safety data are presented for group 1 (former placebo) and Group 2 data are divi
Interventions
- BIOLOGICAL AR101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 3 |
What the finished NCT02993107 record still lists
NCT02993107 is an interventional study that assigns participants to a tested intervention. The registered 388 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which AR101 is the first listed.
NCT02993107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02993107 about?
NCT02993107 is a clinical study titled "PALISADE Follow-on Study (ARC004)". The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
What is the current status of trial NCT02993107?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2016-12-29. Estimated completion is 2019-05-31.
What interventions are being tested in trial NCT02993107?
The interventions under investigation include: AR101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02993107?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02993107's enrollment target sits among peer trials
388 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
- NCT05748613 · 388 participants · NA
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
- NCT06374277 · 388 participants · NA
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI